Lecture on HDAC Inhibitors

James Rusche, PhD, Sr. Vice President, Research and Development, Repligen Corporation, discusses the work his company has done to identify development candidate for Friedreich's Ataxia.

No comments:
Write comments
Recommended Posts × +